---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-281960"
form_type: "8-K"
ticker: "WVE"
cik: "0001631574"
company_name: "Wave Life Sciences Ltd."
filed_at: "2022-11-10T23:59:59+00:00"
generated_at: "2026-06-21T23:04:27.717255+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Wave Life Sciences Q3 2022 net loss $39M; HD trial shows allele-selective mHTT reduction

## Summary
- Net loss of $39.0M vs $6.2M in Q3 2021; revenue $0.3M down from $36.4M due to Takeda amendment.
- SELECT-HD: WVE-003 reduced mHTT by mean 22% (median 30%) at 85 days post single dose; wtHTT preserved.
- WVE-N531 multidosing underway in DMD; muscle biopsy data expected in 4Q 2022.
- Selected WVE-006 as first RNA editing candidate for AATD; CTA submissions expected in 2023.
- Cash $122.0M as of Sept 30, 2022; runway expected to fund operations to end of 2023.

## SEC filing metadata
- accession: 0001193125-22-281960
- form_type: 8-K
- ticker: WVE
- cik: 0001631574
- company_name: Wave Life Sciences Ltd.
- filed_at: 2022-11-10T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1631574/000119312522281960/0001193125-22-281960-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1631574/000119312522281960/d366748d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-281960
- JSON: https://secwatch.observer/filing/0001193125-22-281960.json
- Plain text: https://secwatch.observer/filing/0001193125-22-281960.txt

## Key facts
- Earnings Releases
  Wave Life Sciences Ltd. reported financial results for the quarter ended September 30, 2022.
  - Period: the quarter ended September 30, 2022
  - Result: reported results
  source text: On November 10, 2022, Wave Life Sciences Ltd. (the “Company”) announced its financial results for the quarter ended September 30, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1631574/000119312522281960/0001193125-22-281960-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.